Panagora Asset Management’s Filana Therapeutics FLNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-3,562
Closed -$304K 2277
2021
Q2
$304K Sell
3,562
-1,213
-25% -$65K ﹤0.01% 1519
2021
Q1
$214K Buy
4,775
+2,318
+94% +$91.2K ﹤0.01% 1675
2020
Q4
$17K Buy
2,457
+700
+40% +$6.25K ﹤0.01% 2217
2020
Q3
$20K Buy
+1,757
New +$7.92K ﹤0.01% 2208
2019
Q3
Sell
-37,697
Closed -$46K 2610
2019
Q2
$46K Sell
37,697
-1,385
-4% -$1.57K ﹤0.01% 2102
2019
Q1
$50K Hold
39,082
﹤0.01% 2037
2018
Q4
$33K Sell
39,082
-719
-2% -$827 ﹤0.01% 2088
2018
Q3
$40K Buy
+39,801
New +$60.5K ﹤0.01% 2065
2018
Q1
Sell
-19,699
Closed -$79K 2386
2017
Q4
$79K Sell
19,699
-787
-4% -$3.18K ﹤0.01% 1949
2017
Q3
$83K Buy
20,486
+8,792
+75% +$31.4K ﹤0.01% 1934
2017
Q2
$48K Buy
11,694
+8,604
+278% +$40.6K ﹤0.01% 2081
2017
Q1
$19K Buy
+3,090
New +$14K ﹤0.01% 2186
2014
Q3
Sell
-10,618
Closed -$427K 2344
2014
Q2
$427K Sell
10,618
-244
-2% -$9.03K ﹤0.01% 1436
2014
Q1
$418K Buy
+10,862
New +$383K ﹤0.01% 1491

Other funds holding FLNA

Panagora Asset Management's FLNA Position: Q3 2021 in Review

Panagora Asset Management sold out of Filana Therapeutics (FLNA) in Q3 2021, closing a stake of 3,562 shares — an estimated $304K sold.

Panagora Asset Management first reported a position in FLNA in Q1 2014 and held it in 14 quarters. The position peaked at $427K in Q2 2014. 180 funds tracked by Wall St. Rank hold FLNA as of Q3 2021.

  • Panagora Asset Management reported no remaining Filana Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Panagora Asset Management sold 3,562 Filana Therapeutics shares in Q3 2021, an estimated $304K.
  • Panagora Asset Management first reported a position in Filana Therapeutics in Q1 2014 and held it in 14 quarters.
  • Panagora Asset Management's Filana Therapeutics position peaked at $427K in Q2 2014.
  • 180 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2021.

Based on Panagora Asset Management's 13F filing for Q3 2021, filed 10 Nov 2021.